Home Cart Sign in  
Chemical Structure| 102121-60-8 Chemical Structure| 102121-60-8

Structure of AM580
CAS No.: 102121-60-8

Chemical Structure| 102121-60-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AM580 is the stable retinobenzoic derivative that acts as an agonist of RARα.

Synonyms: CD336; Ro 40-6055; NSC608001

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AM580

CAS No. :102121-60-8
Formula : C22H25NO3
M.W : 351.44
SMILES Code : O=C(O)C1=CC=C(NC(C2=CC=C3C(C)(C)CCC(C)(C)C3=C2)=O)C=C1
Synonyms :
CD336; Ro 40-6055; NSC608001
MDL No. :MFCD00673916
InChI Key :SZWKGOZKRMMLAJ-UHFFFAOYSA-N
Pubchem ID :2126

Safety of AM580

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary microglia 100 μM 12 hours Am580 markedly attenuated TLR agonists-induced iNOS expression, without canceling their basic immune response. PMC8740456
MMTV-wnt1 cells 50 nM 13 days AM580 treatment increased caspase-3 expression in all of the colonies, and in 30% of the colonies induced acinar-like cavitation PMC2891995
HEp-2 cells 20 µM 24 hours AM580 significantly inhibited AdV5 replication in HEp-2 cells PMC6328544
RD cells 20 µM 24 hours AM580 significantly inhibited EV-A71 replication in RD cells PMC6328544
THP-1 cells 20 µM 24 hours AM580 significantly inhibited MERS-CoV replication in THP-1 cells PMC6328544
Vero cells 20 µM 24 hours AM580 significantly inhibited MERS-CoV replication in Vero cells PMC6328544
A549 cells 20 µM 24 hours AM580 significantly inhibited MERS-CoV replication in A549 cells PMC6328544
Calu-3 cells 20 µM 24 hours AM580 significantly inhibited MERS-CoV replication in Calu-3 cells PMC6328544
Huh7 cells 20 µM 24 hours AM580 significantly reduced MERS-CoV replication, viral titers decreased by >3-log10 PMC6328544
ACE2-HeLa cells 20 μM 24 hours AM580 significantly inhibited SARS-CoV-2 replication in ACE2-HeLa cells. PMC8449311
Vero-E6 cells 20 μM 24 hours AM580 significantly inhibited SARS-CoV-2 replication in Vero-E6 cells. PMC8449311
Huh7 cells 20 μM 24 hours AM580 treatment significantly inhibited SARS-CoV-2 replication, as demonstrated by a decrease in viral protein expression and viral RNA copies. PMC8449311
MCF-7 cells 500 nM 24 hours To evaluate the activation effect of AM580 on the RARβ promoter, results showed that AM580 significantly increased the activity of the RARβ promoter. PMC8997856
MDA-MB-231 cells 500 nM 24 hours To evaluate the activation effect of AM580 on the RARβ promoter, results showed that AM580 significantly increased the activity of the RARβ promoter. PMC8997856
H-4-II-E rat hepatoma cells 1 nM to 1 µM 24 hours To evaluate the effect of AM580 on CYP2C22 mRNA expression, results showed that AM580 significantly upregulated CYP2C22 mRNA levels. PMC2882718
Swan71 cells 200 nM 24 to 72 hours To investigate the induction of RARRES1 expression by AM580 in Swan71 cells. Results showed that AM580 significantly induced RARRES1 expression. PMC5701501
BeWo cells 200 nM 24 to 72 hours To investigate the induction of RARRES1 expression by AM580 in BeWo cells. Results showed that AM580 alone did not significantly induce RARRES1 expression, but after pretreatment with 5-aza-2′-deoxycytidine, AM580 significantly increased RARRES1 expression. PMC5701501
JAR cells 200 nM 24 to 72 hours To investigate the induction of RARRES1 expression by AM580 in JAR cells. Results showed that AM580 alone did not significantly induce RARRES1 expression, but after pretreatment with 5-aza-2′-deoxycytidine, AM580 significantly increased RARRES1 expression. PMC5701501
Jeg-3 cells 200 nM 24 to 72 hours To investigate the induction of RARRES1 expression by AM580 in Jeg-3 cells. Results showed that AM580 alone did not significantly induce RARRES1 expression, but after pretreatment with 5-aza-2′-deoxycytidine, AM580 significantly increased RARRES1 expression. PMC5701501
MDCK cells 20 µM 48 hours AM580 significantly inhibited H1N1 virus replication in MDCK cells PMC6328544
Primary trophoblasts 200 nM 48 hours To investigate the induction of RARRES1 expression by AM580 in primary trophoblasts. Results showed that AM580 significantly induced RARRES1 expression. PMC5701501
Mouse mammary epithelial cells 200 nM 48 hours To evaluate the effect of Am580 on CRBP1 expression, results showed that Am580 significantly induced CRBP1 protein expression PMC3680916
MDA-MB-231 cells 200 nM 48 hours Increased RBP1 expression and atRA production PMC8909206
MCF-7 cells 200 nM 48 hours Increased RBP1 expression and atRA production PMC8909206
Monocyte-derived dendritic cells (moDCs) 100 nM 6 days AM580 significantly enhanced the expression levels of ANKRD55 and upregulated IL31RA expression. PMC8801523
HEK293T cells 1 µM 6 hours To assess the metabolic capacity of CYP2C22 for RA, results showed that CYP2C22 converted RA to polar metabolites. PMC2882718
Human MCF-7 cells 200 nM 96 hours To evaluate the effect of Am580 on cell proliferation, results showed that Am580 inhibited cell proliferation PMC3680916
Human MCF-10A cells 200 nM 96 hours To evaluate the effect of Am580 on cell proliferation, results showed that Am580 inhibited cell proliferation PMC3680916
Mouse dorsal root ganglia neurons 5 μM AM580 activated TRPV1-mediated currents and calcium influx PMC3754244
HEK293T cells 100 μM AM580 activated TRPV1-mediated calcium influx PMC3754244

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish (Danio rerio) Zebrafish embryos Water exposure 0.001–0.03 µM 0–120 hpf (hours post-fertilization) To evaluate the effect of AM580 on head skeleton malformations in zebrafish embryos. AM580 significantly increased the Meckel's–palatoquadrate (M–PQ) angle, indicating an effect on head skeleton development. PMC6290702
Mice Tg26 mice (HIV-1 transgenic mice) Oral 0.3 mg/kg/day Daily from the age of 4 weeks to 12 weeks AM580 attenuated proteinuria, glomerulosclerosis, and podocyte proliferation, and restored podocyte differentiation markers PMC3050085
Mice MMTV-Myc transgenic mouse model Oral 0.3 mg/kg/day Daily administration for 50 weeks To evaluate the effect of Am580 on mammary tumor growth and metastasis, results showed that Am580 significantly inhibited tumor growth and lung metastasis PMC3680916
Mice MMTV-neu and MMTV-wnt1 transgenic mice Dietary addition 0.3mg/kg/day Daily, for 40 weeks (neu) and 35 weeks (wnt1) AM580 treatment significantly increased tumor-free survival, reduced tumor incidence and growth of established tumors, and inhibited epithelial hyperplasia PMC2891995
HIV-1 transgenic mice Rapidly progressive renal failure model Mixed in the animal chow 0.3mg/kg/day Daily for a total of 5 weeks AM580 significantly reduced proteinuria, attenuated kidney injury, and improved podocyte differentiation. The renal protective effects were further enhanced when combined with the PDE4 inhibitor roflumilast. PMC3326224
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) Intraperitoneal injection 1 mg/kg or 2 mg/kg Administered every other day, starting on day 11 post immunization until day 21 p.i. AM580 was ineffective in suppressing EAE development and had no significant effect on demyelination and leukocyte infiltration PMC6804666
Zucker diabetic fatty rats Diabetic cardiomyopathy model Oral gavage 1 mg/kg/day Daily for 16 weeks Am580 attenuated diabetes-induced cardiac dysfunction and the pathological alterations, by improving glucose tolerance and insulin resistance; facilitating Akt activation and glucose utilization, and attenuating oxidative stress and interrelated MAP kinase and NF-κB signaling pathways. PMC3594065
Mice Trpv1+/+ and Trpv1−/− mice Intraplantar injection 100 nmol/20 μl Single injection, observed for 2 hours AM580 induced paw edema and nociceptive behaviors via TRPV1 PMC3754244
HDPP4 transgenic mice MERS-CoV infection model Intraperitoneal injection 12.5 mg/kg/day Once daily for 3 days AM580 significantly improved the survival rate of MERS-CoV-infected mice, reduced body weight loss and lung viral load PMC6328544
5xFAD transgenic mice Alzheimer's disease model Intracerebroventricular delivery 28.5 mM Continuous for 7 or 28 days Intracerebroventricular delivery of Am580 in 5xFAD mice reduced significantly the fraction of (neurotoxic) iNOS + microglia and increased the fraction of (neuroprotective) TREM2 + microglia. Furthermore, intracerebroventricular delivery of Am580 prevented neurodegeneration induced by microbial TLR agonists. PMC8740456
Rats Vitamin A-deficient rats Oral 30 µg AM580 Single dose, euthanized after 6 hours To evaluate the effect of AM580 on CYP2C22 mRNA expression, results showed that AM580 significantly increased CYP2C22 mRNA levels. PMC2882718

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.28mL

14.23mL

2.85mL

1.42mL

28.45mL

5.69mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories